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Lamotrigine, a FDA approved antiepileptic drug is widely used in the treatment of epilepsy and bipolar disorder. However, 
poor aqueous solubility and low dissolution rate limit its oral absorption leading to a delayed onset of action with reduced 
therapeutic effect. The present study aims for the development of formulation and characterization of lamotrigine-salicylic acid 
crystalline product for the improvement of oral release and absorption for better management of epilepsy. The crystalline 
product of LT are developed with SA at 1:1, 2:1, 3:1 molar ratios by solvent evaporation method. The experimental crystals 
have been characterized by different analytical techniques such as fourier transform infrared (FTIR) spectroscopy, differential 
scanning calorimetry (DSC), powder X-ray diffraction (PXRD) etc. Presence of characteristic peaks for peptide in the 
experimental crystalline products in FTIR spectra indicates formation of strong covalent bond between LA and SA. In the DSC 
thermograms, melting endotherm of the formulations showed different melting points than pure LT. PXRD data depicted sharp 
peaks for the formulations, which further justified the successful formation of a new crystalline phase. Dissolution profile of the 
experimental crystal (L1S1 at 1:1 molar ratio) in simulated gastric fluid was higher than that of the pure drug and other 
formulations. The optimized crystalline product of LT may be used for the better oral treatment of epilepsy with early onset of 
action after successful in vivo studies.  
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Poor aqueous solubility associated with low dissolution 
rate of many therapeutic agents remains as the major 





can be characterized as abnormal electrical activities 
generated within the brain, which may affect a local area 
(partial seizure) or the entire brain (generalized seizure)
2
. 
The main goal for the management and control of 
epilepsy is the timely delivery of the drug with required 
therapeutic concentration to elicit early onset of action 
so as to reduce frequency and severity of seizures. 
However, Low solubility delays the onset of action, 
which directly limits the therapeutic efficacy of 
pharmaceutical agents to achieve desired clinical 
outcome. Among several techniques for the 
improvement of dissolution profiles of therapeutic 
agents such as solid dispersion, salt formation, 
complexation, nanocarrier system, etc., crystallization 
method has been employed as a suitable technique in 
pharmaceutical research
2,3
. A crystal is a type of 
molecular complex which contains two or more different 
molecules, bound together through covalent interactions 




This modified formulation 
accepts pharmaceutically compatible guest molecules 
into its crystal lattice along with the active 
pharmaceutical ingredient (API) without interfering into 
their molecular arrangements
4
. Crystalline products are 
considered to be products of more rational design with 
higher stability as most of the crystallizing agents exist 
as stable solid forms at room temperature.  
In formulation development, crystallization approach 
holds the uniqueness as it neither affects the 
pharmacological properties of incorporated drug 
molecule, nor changes its molecular structure, but alters 
several physicochemical characteristics of the entrapped 
drug molecule including melting point, solubility, 
permeability, tabletability, bioavailability etc
5,6
. Another 
advantage associated with crystals is their potentiality to 
be employed with all most all types of APIs including 
acidic, basic, and non-ionisable molecules
6
. 
Lamotrigine (LT), a Food and Drug Administration 
(FDA) approved anti-epileptic drug, is widely 
recommended for the treatment of epilepsy and 








Chemically, LT is  
6-(2,3-dichlorophenyl)- 1,2,4-triazine-3,5-diamine. 
Lamotrigine, a phenyl triazene class of anti-epilepsy 
drug is recommended for the treatment of primary and 




LT significantly delays the incidence of repeat 
episodes with fewer side effects and is well tolerated 
in epileptic patients. The possible mechanism of 
action involves inhibition of voltage dependent Na
+
 
channels, which leads to sharp reduction in the release 




However, being a BCS class II drug, its absorption 
and bioavailability is dissolution rate limited. Thus, poor 
solubility linked with low dissolution rate delays its 















etc. have been reported over the past 
years for the improvement of dissolution rate and oral 
bioavailability of LT. Shinde et al., reported solid 
dispersion technique to enhance the solubility and 
dissolution characteristics of LT
11
. LT pellets were 
prepared with solid dispersions with 
polyvinylpyrrolidone K30 (PVP K30) and 
polyethyleneglycol 6000 as excipients by solvent 
evaporation method. The optimized formulation (PVP 
K30) at 1:5 drug:excipient molar ratio showed enhanced 
dissolution profile during the experimental study period. 
In another study, Chappa et al. investigated the structural 
and pharmaceutical properties of two novel cocrystals of 
LT formulated with maleic acid and malonic acid. The 
experimental cocrystals were evaluated by different in-
vitro techniques
14
. The selected cocrystal formulations 
were subjected to in-vitro dissolution studies in 0.1 N 
HCl and compared with pure LT. Results showed a 
significantly higher dissolution rate of optimized LT-SA 
crystal than pure API. 
However, crystallization technique of LT with 
salicylic acid for the enhancement of its solubility and 
release of drug in active form in simulated gastric 
fluid has not been reported yet. Thus, the present 
study aims to develop crystalline product of LT with 
salicylic acid and to evaluate their in vitro 
characteristics in order to establish an optimized 
formulation for improved release and oral absorption 





LT was obtained as a gift sample from Unichem 
Pvt. Ltd., Madhya Pradesh, India. Salicylic acid (SA) 
was procured from Sisco Research Laboratories, 
Maharashtra, India. Ethanol was purchased from 
Merck Specialties Pvt. Ltd., Maharashtra, India. All 
other chemicals used were of analytical grade. 
 
Method of crystal formation 
The crystalline product of LT along with SA was 
prepared by conventional solvent evaporation 





accurately weighed amount of LT was mixed with 
required quantity of SA. The mixture was then 
dissolved in ethanol (50% v/v). After that the resultant 
solution was dried at 40-50°C for 72 h. The organic 
solvent was slowly evaporated during the entire 
process to induce crystallization. Finally the 
crystallized products were recovered and used for 




Fourier transform infrared (FTIR) spectroscopy 
For the FTIR study, the pure drug (LT), excipient 
(SA) and different formulations (LT-SA crystals) 
were mixed properly with KBr (IR grade) in the ratio 
of 100:1 in separate vessels
16,17
. Corresponding pellets 
were prepared by applying a pressure of 5 tons for  
5 min in a hydraulic press. The thin pellets were 
formed, which were then scanned with the help of a 
FTIR spectrophotometer (JASCO, FT/IR-4100) over 
a wave number range of 4000cm
-1
 to 400 cm
-1 
using 
spectra manager software version 2.0. 
 
Differential scanning calorimetry (DSC) 
DSC measurements for pure drug, SA and all the 
selected crystal formulations were carried out using a 





The temperature and heat flow of the instrument was 
calibrated using an Indium (m.p. 156.6°C) and zinc 
standards (m.p. 419.6°C). During the experiment, 
weighed amount of test samples (6 mg) were analyzed 
in crimped aluminum pans with pin-hole pierced lids. 
Throughout the experiment, N2 atmosphere was 
maintained and a heating rate of 10°C min
-1 
(within a 
temperature range of 30-300°C) was employed. 
 
Powder X-ray diffraction (PXRD) 
XRD study was carried out for the developed 
crystal products to get the information about the 
crystal structure, chemical composition along with 
physical changes in the materials. For the study, about 
1 mg of dry powdered sample was placed on the glass 
slide and analyzed with a powder X-ray 
diffractometer (Ultima, IV, Japan)
19,20
 During the 
experiment, an X-ray power of 40 kV/40 mA at a 




detection angle (2θ), (2° - 75°) was employed for  
120 seconds. 
 
In-vitro drug release study 
The in-vitro drug release study for the selected 
crystalline product was performed according to US 
pharmacopoeia XXIII rotating paddle method in a 
dissolution apparatus (Dissolution tester (USP) 
TDT06L, Electrolab). For the experiment, weighed 
amount of the formulations placed in 900 ml of 0.1 N 
HCl at pH 1.2 in the dissolution vessel and set at 50 
rpm rotation speed. The temperature during entire 
period of dissolution study was maintained at 37°C ± 
0.5°C. At pre-determined time intervals (5, 10, 20, 30, 
60 min), about 10 ml of samples were withdrawn 
from the dissolution chamber along with simultaneous 




The samples were 
filtered and analyzed by UV-Visible 
spectrophotometer (JASCO V-630, Japan) at 267 nm 
against 0.1 N HCl as blank. All the studies were 
performed in triplicate. 
 
Results and Discussion 
 
Formulation development 
Crystallization technique is an emerging strategy to 
improve dissolution rate and oral bioavailability of 
poorly water soluble drugs. The technique is simple, 
devoid of any critical formulation steps, thus easy to 
standardize for industrial scale. In the present work, 
crystalline products of LT, a widely used antiepileptic 
drug, was prepared with SA as excipient. Various 
formulations were developed by varying molecular 
ratio of drug and excipient. In our work, the amount 
of SA was kept constant, whereas amount of LT was 
varied under identical experimental conditions. 
Among all the developed formulations, three 
formulations (L1S1, L2S1 and L3S1) with molar 
ratios such as 1:1, 2:1, 3:1 of LT with SA have been 
reported. The formulation composition of various 
crystal products was depicted in Table 1.  
 
The schematic representation of LT-SA crystal 
product has been illustrated in Fig. 1. It predicted 
formation of peptide bond in between the acidic group 
of SA with the amine group (NH2) of LT with the 
removal of water. This type of bond is usually very 
strong covalent bonds which remain stable to 
hydrolysis, however, in presence of acidic pH (pH 2-
3), it can be readily broken to liberate the entrapped 
drug molecule.  
 
FTIR study 
FTIR study was conducted to assess the 
incompatibility (if any) between various functional 
groups of API and the excipient and also to justify the 
formation of crystals. Data showed few changes in the 
characteristic peaks of experimental formulations as 
compared to free drug, which indicates that crystals 
were formed (Fig. 2). When the spectra of pure drug, 
and the selected crystal products were compared, the 
major functional groups of LT that is 3500 cm
-1
 (NH2 
symmetric stretching), 850-550 cm
-1
 (C-Cl stretching 
vibration), 3000-3250 cm
-1
 (aromatic C-H stretching 
vibration) etc. were found in all the experimental 
crystal formulations (L1S1, L2S1, L3S1). However, 
shifting of some peaks was clearly observed in the 
FTIR data of crystal formulations. Particularly the 











L1S1 1.875 1 1:1 50% Ethanol 
L2S1 3.750 1 2:1 50% Ethanol 
L3S1 5.625 1 3:1 50% Ethanol 
 
 
Fig. 1 — Schematic representation of LT-SA crystal formation and release of the drug under gastric acidic pH condition. 




sharp peak observed for the drug at 3445.21 cm
-1
 due 
to the presence of NH2 group (symmetric stretching 





 (L2S1), and 3832.83 cm
-1
 
(L3S1) in the tested formulations. A strong peak was 
observed at 1298.82 cm
-1
 (L1S1, L3S1) and 1301.72 
cm
-1
 (L2S1) in the crystal products (C-N stretching 
vibration for aromatic amine), which was absent in 
the FTIR spectrum of the pure drug. This could be 
attributed to the formation of strong covalent bond 
(peptide bond) between the COOH group of SA and 
NH2 group of LT during formation of crystal 
structure. Similarly the peak at 791.636 cm
-1
 observed 
for LT (C-Cl stretching) was found to be shifted to 
794.528 cm
-1
 (L1S1), 708.712 cm
-1
 (L2S1) and 
795.493 cm
-1
 (L3S1) respectively. In a nutshell, 
shifting in the characteristic peaks between the spectra 
of pure drug, excipient and formulation as well as 
appearance of new peaks in the crystal products 
justified the formation of new intermolecular bonds 
among the functional groups of LT and SA which 
might lead to the formation of novel crystal structure. 
 
DSC study 
DSC experiment was carried out to depict the 
thermal behavior of the crystal form in relation to the 
individual components. DSC thermogram of LT and 
selected crystal products (L1S1, L2S1 and L3S1) 
were presented in Fig. 3. Data showed sharp 
endothermic peaks of LT at 215°C. Experimental 
 
 
Fig. 2 — FTIR spectra of pure drug (LT), excipient (SA) and 
crystal products (L1S1, L2S1, L3S1) 
 
 
Fig. 3 — DSC thermogram of pure drug, excipient (SA) and the crystal products (L1S1, L2S1, L3S1) 




crystals of LA-SA showed sharp endothermic peaks at 
237.75, 226.01, and 201.35°C. The sharp endothermic 
values of crystal form and the individual component 
agreed with the melting range in the melting point 
determination. It was found that the thermal profile of 
crystalline products were distinct with different 
melting transitions than that of the indivisual 
components (LT, SA) which indicates formation of a 
novel crystal phase. The endothermic transitions 
further signified absence of any absorbed solvent or 
water molecules in the synthesized crystalline product 
and thus stable nature of the crystal phase. 
 
PXRD study 
PXRD is a very useful analytical technique, which is 
employed for the phase identification of a crystal 
structure and also reveals necessary clue on unit cell 
dimensions. It actually measures the diffraction pattern 
of crystalline material
22
. In XRD study, each API 
produces a specific pattern depending on the structure of 
its crystal lattice. Similarly, each polymorph, crystal or 
salt forms also have its own specific pattern. PXRD 
pattern of pure LT and selected crystal products were 
depicted in Fig. 4. For LT, the crystalline peaks were 
located at 12.39°, 17.35°, 25.44°, 26.68°, 27.78° and 
28.33° (2Ɵ). Some new peaks were also observed in the 
prepared crystals. In our study, among the crystalline 
products, L1S1 showed a much sharper peak as 
compared to other formulations L2S1 and L3S1. The 
smaller peaks in L2S1 and L3S1 may be attributed to the 
phenomenon of amorphyzation. While comparing the 
graphs, each graph showed 100% relative intensity at 
different 2Ɵ angles, which are the clear indications of 
successful formation of crystal lattice. 
Debye-Scherrer’s formula was employed to find 
out other characteristic properties like particle size, 
strain and dislocation density which are tabulated in 
(Table 2).  
Crystallite size was calculated using following 
equation: 
 
D = 0.9/βcos … (1) 
 
The particle strain in lattice was determined from 
the equation. 
 
 = β/4tan … (2) 
 
Where,  = Strain, β = Full Width Half maxima 
(FWHM) 
 
D = Crystallite size,   = Wavelength 
 
The dislocation density (), which represents the 
amount of defects in the sample is defined as the 
length of dislocation lines per unit volume of the 




 … (3) 
 
Particle size was found lowest in case of L1S1 as 
compare to pure LT as well as other formulations. 
The strain and dislocation value were found higher as 
compare to other formulations. The above mention 
changes may due to the binding of lamotrigine with 
salicylic acid. 
 
In vitro drug release study 
In vitro drug release study is a key physicochemical 
parameter for all solid oral dosage forms that actually 
 
 
Fig. 4 — PXRD data of pure drug and the crystal formulations (L1S1, L2S1, L3S1) 
 
Table 2 — Lamotrigine-salicylic acid crystal products 
characteristics from XRD analysis 
Formulation Particle size (nm) Strain Dislocation density 
(*104) 
LT 77.31 0.337 1.67 
L1S1 54.75 0.398 3.34 
L2S1 78.76 0.371 1.61 
L3S1 76.23 0.058 1.72 
 




characterizes how an API is extracted out of the solid 
dosage form. Appropriate selection of the in vitro 
experimental conditions that simulate the in vivo 





Thus, to quantitatively elucidate the 
effect of solid-state modification on the dissolution 
characteristics as well as to select optimized product, in 
vitro dissolution studies were conducted for pure LT 
and LT-SA crystalline products (Fig. 5). The 
experiment was carried for 60 min in simulated gastric 
fluid (0.1 N HCl, pH 1.2) as the release medium. From 
the dissolution data, it was found that among the 
selected formulations, L1S1 (1:1 molar ratio) showed 
highest cumulative % drug release of 97.11 % within 
10 min study period as compared to other formulations 
and pure drug. Among LT-SA crystals, L2S1 and L3S1 
showed lesser amount of cumulative % drug release 
than pure LT. L1S1 thus could be selected as the 
optimized formulation, owing to its higher drug release 
property. The higher drug release property of L1S1 
might be attributed to the higher compatibility between 
LT and SA with proper supramolecular arrangement of 
the subunits in the newly formed crystal lattice. 
 
Formation of the peptide bond between the LT and 
SA was the uniqueness of this study, which was 
depicted schematically in Fig. 1. The same was also 
confirmed from the newly formed peaks observed in 
the FTIR spectra of crystal products. Though peptide 
bond is a type of strong covalent bond and thus seems 
difficult to split, but this can be easily broken under 
acidic pH condition (pH 3-4). In our case, simulated 
gastric fluid (pH 1.2) was used as the drug release 
medium, which might have helped to break the strong 
peptide bond easily to release the entrapped drug 
molecule. Thus the experimental crystal product 
would remain reasonably stable during the entire 
period of storage due to existence of strong covalent 
bond as well as it would also show satisfactory drug 
release property upon oral administration in acidic 
medium. These unique characteristics of the 
developed formulation would be certainly beneficial 
to improve their clinical applicability. 
 
Conclusion  
The study reported a simple, industrially viable, 
standardized method for the development of stable 
crystalline product of LT using SA as the excipient to 
enhance dissolution rate and oral absorption of LT for 
improved management of epilepsy. FTIR confirmed 
successful formation of crystal of LT with SA (peptide 
bond formation) and DSC study further depicted 
absence of any chemical reaction between the drug and 
the excipient. Out of the selected formulations, L1S1 
showed sharp peak as depicted from XRD study, which 
further justified successful formation of new crystal 
structure. The dissolution rate was higher for L1S1 as 
compared to other formulations and pure drug during 
the experimental time period. Owing to its satisfactory 
drug release profile in simulated gastric fluid (97.11 % 
within 10 min), L1S1 was reported as the optimized 
crystalline product. However, further in vivo studies are 
specifically warranted to establish the formulation for 
its future clinical applications in epilepsy after oral 
administration. 
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